CLINICAL EVALUATION OF SU-10704 IN ANXIOUS PATIENTS
Abstract
In this preliminary study, SU-10704 proved to be effective in decreasing the level of psychopathology in chronic, primarily anxious clinic patients. The therapeutic effect was most marked in those patients in whom the "emotional" symptoms predominated over the "somatic" ones and was obtained through amelioration of the emotional symptom components of their illness. Side effects were minimal and apparently dose/weight related. In most patients, side reactions did not require discontinuation of medication, but disappeared after a few days or after reduction of dosage. No effects on blood pressure were noticed and only a mild bradycardic effect was seen. The question has to be left open whether placebo alone would also have affected emotional symptoms more than somatic ones.
On the basis of this preliminary single-blind study, it appears recommendable to evaluate SU-10704 in a more rigorous double-blind study.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
